CALL FOR PAPERS

Author Information

CERTIFICATE

IMPACT FACTOR 2021

Subject Area

Life Sciences / Biology
Architecture / Building Management
Asian Studies
Business & Management
Chemistry
Computer Science
Economics & Finance
Engineering / Acoustics
Environmental Science
Agricultural Sciences
Pharmaceutical Sciences
General Sciences
Materials Science
Mathematics
Medicine
Nanotechnology & Nanoscience
Nonlinear Science
Chaos & Dynamical Systems
Physics
Social Sciences & Humanities

Why Us? >>

Open Access
Peer Reviewed
Rapid Publication
Life time hosting
Free promotion service
Free indexing service
More citations
Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the crystal study

Author:

Dan Călugăru and Mihai Călugăru

Subject Area:

Health Sciences

Abstract:

The authors are commenting the article entitled “Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the Crystal study” published by Larsen et al. in Ophthalmology Retina 2018;2(2):134-142. The conclusion resulting from this article is that regardless of the antiangiogenic agents chosen (e.g., bevacizumab/ranibizumab), the treatment paradigms used (e.g., treat-and-extend/pro re nata/fixed-interval/escalated algorithm), the patient age, the baseline best-corrected visual acuity, and the form of central retinal vein occlusion (ischemic/nonischemic occlusion), the efficacy of treatment depends primarily on the promptness of the therapy after the onset of the retinal vein occlusion.

PDF file: